“…This drug, which is otherwise used to control radiation-and chemotherapy-induced or postoperative nausea and vomiting, might act on the intestinal, the hepatic, and the systemic level (Gan, 2005). The effects of tropisetron, which comprise not only modulatory effects on neurons but also anti-inflammatory properties, are possibly mediated not solely through 5-HT 3 R (Thompson and Lummis, 2006;Mousavizadeh et al, 2009). We focused our studies on intestinal and hepatic effects of tropisetron, and we also tested the more specific 5-HT 3 R antagonist palonosetron to find out whether or not the beneficial effects are rather related to the inhibition of the 5-HT 3 R. The studies were performed using a well established genetic model of obesity, the ob/ob mouse (Anstee and Goldin, 2006), which is characterized not only by the absence of functional leptin but also by thymic atrophy and defective immune responses concerning dendritic, regulatory, and natural killer cells (Macia et al, 2006;Ilan et al, 2010).…”